The Asia-Pacific seasonal influenza vaccine industry is expected to witness rapid growth in the coming decade, with a number of key factors expected to influence this growth. Some of these factors include a rising awareness within the Asia-Pacific region about the threat of pandemic influenza, and an increased vaccination coverage aided by government support. These features of the future seasonal influenza vaccine industry in Asia-Pacific will see the market reach a total of $1.88 billion by the end of 2018, from $1.02 billion in 2011. This suggests a CAGR growth rate of 9% between these years.
Growth in the industry in recent years can be attributed partly to a change in attitude among patient populations in the Asia-Pacific region. The current opinion is that preventative healthcare is better than curative healthcare. This is particularly apt when talking about seasonal influenza, which can be treated through two options; vaccines and antiviral therapies. Vaccines are seen as the more preventative solution, as opposed to antiviral therapies which are seen as more curative. This change in mindset has also the decision of seasonal influenza vaccine manufacturers to begin trading in Asia-Pacific.
There are a number of key restraints to businesses that want to operate in the Asia-Pacific seasonal influenza vaccine industry. These include the variable demand for vaccines in each country in the Asia-Pacific region, and having limited production capacity. These production capacity issues are expected to be reduced by the increasingly prevalent technique of using cell culture vaccines as opposed to traditional egg based manufacturing of seasonal influenza vaccines. The use of cell culture vaccines is expected to aid increase vaccination coverage in the Asia-Pacific region.
In terms of country breakdown, the most attractive markets for seasonal influenza vaccines include the Philippines, Malaysia, Singapore and Australia. These four countries are expected to post healthy growth between 2011 and 2018.
Research and development of seasonal influenza vaccines is currently strong, with around 50% of the pipeline in Phase II and Phase III. Currently manufacturers in the industry are looking at acquiring new technologies and strengthening their presence by acquiring smaller biotech companies.
For more information on the Asia-Pacific seasonal influenza vaccines industry, see the latest market research: Asia-Pacific seasonal influenza vaccines industry
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.